Literature DB >> 20727039

Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1.

John P Graham1, Kelly M Arcipowski, Gail A Bishop.   

Abstract

CD40 plays a vital role in humoral immunity, via its potent and multifaceted function as an activating receptor of various immune cells, most notably B lymphocytes. The Epstein-Barr virus-encoded transforming protein latent membrane protein 1 (LMP1) serves as a functional mimic of CD40 signals to B cells but lacks key regulatory controls that restrain CD40 signaling. This allows LMP1 to activate B cells in an abnormal manner that can contribute to the pathogenesis of human B-cell lymphoma and autoimmune disease. This review focuses upon a comparative analysis of CD40 versus LMP1 functions and mechanisms of action in B lymphocytes, discussing how this comparison can provide valuable information on both how CD40 signaling is normally regulated and how LMP1 disrupts the normal CD40 pathways, which can provide information of value to therapeutic design.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20727039     DOI： 10.1111/j.1600-065X.2010.00932.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


  55 in total

1.  Genome-wide siRNA screen for mediators of NF-κB activation.

Authors:  Benjamin E Gewurz; Fadi Towfic; Jessica C Mar; Nicholas P Shinners; Kaoru Takasaki; Bo Zhao; Ellen D Cahir-McFarland; John Quackenbush; Ramnik J Xavier; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells.

Authors:  Zachary L Pratt; Jingzhu Zhang; Bill Sugden
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Authors:  A Chanut; F Duguet; A Marfak; A David; B Petit; M Parrens; S Durand-Panteix; M Boulin-Deveza; N Gachard; I Youlyouz-Marfak; D Bordessoule; J Feuillard; N Faumont
Journal:  Leukemia       Date:  2013-09-23       Impact factor: 11.528

Review 4.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

5.  TRAF6 is a critical regulator of LMP1 functions in vivo.

Authors:  Kelly M Arcipowski; Laura L Stunz; Gail A Bishop
Journal:  Int Immunol       Date:  2013-10-29       Impact factor: 4.823

Review 6.  Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

7.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

Review 8.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

9.  LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Authors:  Shi-Dong Ma; Xuequn Xu; Julie Plowshay; Erik A Ranheim; William J Burlingham; Jeffrey L Jensen; Fotis Asimakopoulos; Weihua Tang; Margaret L Gulley; Ethel Cesarman; Jenny E Gumperz; Shannon C Kenney
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

10.  Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.

Authors:  Kayla A Martin; Lena N Lupey; Italo Tempera
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.